Form 4: TriSalus Life Sciences Executive Receives Stock Options and Restricted Stock Units

Bryan F. Cox, Chief of Research at TriSalus Life Sciences, reports the acquisition of stock options and restricted stock units in the company.

Summary

• Bryan F. Cox, Chief of Research at TriSalus Life Sciences, filed a Form 4 detailing changes in beneficial ownership.
• On January 27, 2025, Cox was granted 10,625 restricted stock units (RSUs) payable in common stock, vesting in four equal annual installments starting January 1, 2025, contingent on continued service.
• Cox also received an employee stock option to purchase 63,750 shares of common stock at an exercise price of $5.30.
• The stock options vest over time, with one-fourth vesting on January 1, 2025, and the remainder vesting monthly thereafter, also contingent on continued service.
• Following these transactions, Cox directly owns 97,007 shares of TriSalus Life Sciences common stock and holds options for 63,750 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity suggests confidence in the company's future, but it's a routine filing.

Positives

• The grant of RSUs and stock options to a key executive like the Chief of Research suggests an incentive to align their interests with the company's long-term success.
• The vesting schedules for both the RSUs and stock options encourage continued service and commitment from the executive.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest an expectation of continued service from the executive.

Industry Context

Form 4 filings are standard practice and provide transparency into the compensation and equity ownership of company insiders. This filing indicates that TriSalus Life Sciences is using equity-based compensation to incentivize its executives, which is a common practice in the biotech industry.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biotech industry to attract and retain talent, particularly in research and development roles.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry norms, designed to incentivize long-term performance and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's performance.
• Employees may see this as a positive indicator of the company's commitment to its leadership team.

Key Dates